Samsung Biologics: geographic diversification is a sound business decision
South Korean contract development and manufacturing organisation (CDMO) Samsung Biologics has been on a steep upward growth trajectory since receiving…
All articles by Dominic Tyer
Dominic Tyer
Dominic Tyer is a Senior Editor at GlobalData overseeing PharmSource’s editorial content. He has more than 25 years of pharmaceutical publishing experience as a journalist and editor at leading UK, European and global industry titles. Contact Dom.
-
-
BIO 2026: Indiana, biopharma investment and the Lilly effect
The US drive to onshore biopharmaceutical manufacturing has yielded billions of dollars of industry investment, raising the stakes for states…
-
BIO 2026: Cell and gene therapy firms outline their use of AI in manufacturing
Complexity is inherent to cell and gene therapy and that includes its manufacturing, where moving towards producing products at a…
-
Dangerous waters: Geopolitics, supply chains and access to medicines
Shortages of medicines for conditions such as diabetes, attention deficit hyperactivity disorder (ADHD) and hormone replacement therapy (HRT) have long…
-
Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities
Manufacturing deals saw an unusual burst of activity recently, with a spike in the number of contract development and manufacturing…
